Biotech Values

[drbio45]

ACOR - There is a lot of doubts surrounding Fampridine which is surprising to me. The clinical studies clearly show that the drug works in 30 - 40% of MS patients.

it doesn't work in 30 to 40 percent, maybe 20percent


Other drugs slow the disease progression, but this one actually improves their functional abilities.

this doesn't even slow the disease progression, it only helps them walk faster. Is that a good reason to take bird poison that can cause seizures.

The only way to determine whether the drug works is to try it & once their on it I doubt they will be taken off no matter if no improvement is actually shown.

if they don't improve why would they stay on, unless they are Acorda shareholders? It doesn't even make them feel better


The label does not require that an improvement be shown or limit the duration on drug.

I believe the 7% royalty to ELAN you referred to in a previous message is for manufacturing the drug. ELAN supplies the drug for US and ex. Total milestones to ELAN are $15 million.